Abbreviations
MOBO
na
210
na
Phase:
2
Open label
NSCLC
EGFR ex20ins MT
meta
L3
General Inclusion Criteria all cohorts: dose escalation, antidiarrhea prophylaxis, dose escalation combination, expansion, and extension: Have histologically or cytologically confirmed locally advanced (and not a candidate for definitive therapy) or metastatic NSCLC disease (Stage IIIB or IV) or other solid tumors. For all cohorts except Expansion Cohort 7, the locally advanced or metastatic disease is NSCLC. For Expansion Cohort 7, the locally advanced or metastatic disease is any solid tumor other than NSCLC. Must have sufficient tumor tissue available for analysis. Must have measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1. Male or female adult participants (aged 18 years or older, or as defined per local regulations). Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. Minimum life expectancy of 3 months or more. Adequate organ function at baseline. Normal QT interval on screening el
Previously received TAK-788. Received small-molecule anticancer therapy (including cytotoxic chemotherapy, and investigational agents, ≤ 14 days prior to first dose of TAK-788 (except for reversible EGFR TKIs [that is, erlotinib or gefitinib], which are allowed in the dose escalation and expansion cohorts up to 7 days prior to the first dose of TAK-788). Received antineoplastic monoclonal antibodies including immunotherapy within 28 days of the first dose of TAK-788. Have been diagnosed with another primary malignancy other than NSCLC except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy. Note: This exclusion criteria does not apply to Expansion Cohort 7. Received radiotherapy <=14 days prior to the first dose o